• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

作者信息

Sebastian T, Rajeeve S, Farzana T, Firestone R, Jurgens E, Miller K, Costa B, Lesokhin A, Tan C, Shah G, Korde N, Landau H, Scordo M, Hassoun H, Maclachlan K, Shah U, Hultcrantz M, Derkach A, Nemirovsky D, Giralt S, Usmani S Z, Mailankody S, Hashmi H

机构信息

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Blood Cancer J. 2025 Aug 14;15(1):137. doi: 10.1038/s41408-025-01343-4.

DOI:10.1038/s41408-025-01343-4
PMID:40813765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12354680/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428f/12354680/bbc9a02e181f/41408_2025_1343_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428f/12354680/bbc9a02e181f/41408_2025_1343_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428f/12354680/bbc9a02e181f/41408_2025_1343_Fig1_HTML.jpg

相似文献

1
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.达雷妥尤单抗难治性对复发难治性多发性骨髓瘤CAR T细胞治疗后临床结局的影响。
Blood Cancer J. 2025 Aug 14;15(1):137. doi: 10.1038/s41408-025-01343-4.
2
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.复发或难治性多发性骨髓瘤患者中，贝兰他单抗马福多汀、硼替佐米与地塞米松联合用药对比达雷妥尤单抗、硼替佐米与地塞米松联合用药的患者报告结局（DREAMM-7）：一项3期、开放标签、随机对照试验的结果
Lancet Haematol. 2025 Jul 15. doi: 10.1016/S2352-3026(25)00163-2.
3
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.SCHOLAR-1 标准对侵袭性 B 细胞淋巴瘤嵌合抗原受体 T 细胞治疗疗效的影响：真实世界的 GELTAMO/GETH 研究。
Transplant Cell Ther. 2023 Dec;29(12):747.e1-747.e10. doi: 10.1016/j.jtct.2023.08.026. Epub 2023 Sep 1.
4
ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy.ASTCT 实践指南委员会关于嵌合抗原受体 T 细胞治疗失败后复发/难治性多发性骨髓瘤的评估和管理的调查。
Transplant Cell Ther. 2024 Aug;30(8):750-759. doi: 10.1016/j.jtct.2024.04.007. Epub 2024 Apr 12.
5
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review.达雷妥尤单抗/抗CD38单克隆抗体难治性多发性骨髓瘤患者的治疗：一项系统评价
Cancer Med. 2025 Mar;14(5):e70585. doi: 10.1002/cam4.70585.
6
Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.新型单克隆抗体治疗复发/难治性多发性骨髓瘤疗效与安全性的系统评价和荟萃分析
Oncotarget. 2017 May 16;8(20):34001-34017. doi: 10.18632/oncotarget.16987.
7
Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse.复发/难治性多发性骨髓瘤靶向B细胞成熟抗原嵌合抗原受体T细胞疗法治疗抗原阴性复发的研究进展
Best Pract Res Clin Haematol. 2025 Jun;38(2):101632. doi: 10.1016/j.beha.2025.101632. Epub 2025 May 15.
8
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.双特异性抗体作为复发/难治性多发性骨髓瘤与BCMA嵌合抗原受体T细胞疗法之间的桥梁。
Blood Cancer Discov. 2025 Jan 8;6(1):38-54. doi: 10.1158/2643-3230.BCD-24-0118.
9
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.《复发/难治性多发性骨髓瘤临床实践中基于抗CD38治疗的共识指南与建议：来自泛太平洋多发性骨髓瘤工作组》
Clin Hematol Int. 2025 Aug 8;7(3):36-59. doi: 10.46989/001c.141401. eCollection 2025.
10
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.嵌合抗原受体 T 细胞疗法治疗骨髓瘤：我们现在处于什么位置，以及需要什么才能将嵌合抗原受体 T 细胞推进到更早的治疗线？美国移植和细胞治疗学会专家小组意见。
Transplant Cell Ther. 2024 Jan;30(1):17-37. doi: 10.1016/j.jtct.2023.10.022. Epub 2023 Oct 31.

本文引用的文献

1
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤中标准治疗药物idecabtagene vicleucel与cilta-cabtagene autoleucel的比较。
J Clin Oncol. 2025 May;43(13):1597-1609. doi: 10.1200/JCO-24-01730. Epub 2025 Feb 18.
2
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.依达卡替尼治疗多发性骨髓瘤髓外病变的疗效分析
J Hematol Oncol. 2024 Jun 6;17(1):42. doi: 10.1186/s13045-024-01555-4.
3
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
标准 care 嵌合抗原受体 T 细胞疗法治疗复发/难治性多发性骨髓瘤患者的骨外髓外疾病对结局的影响。
Blood Cancer J. 2024 May 31;14(1):90. doi: 10.1038/s41408-024-01068-w.
4
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.B 细胞成熟抗原导向嵌合抗原受体 T 细胞疗法治疗复发/难治性多发性骨髓瘤患者结局预测模型的建立和验证。
J Clin Oncol. 2024 May 10;42(14):1665-1675. doi: 10.1200/JCO.23.02232. Epub 2024 Feb 15.
5
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.复发/难治性多发性骨髓瘤患者接受 idecabtagene vicleucel 治疗后出现难治或早期进展的相关因素：美国骨髓瘤免疫治疗联盟真实世界经验。
Haematologica. 2024 May 1;109(5):1514-1524. doi: 10.3324/haematol.2023.283888.
6
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.BCMA 或 GPRC5D 靶向免疫疗法治疗多发性骨髓瘤中抗原逃逸的机制。
Nat Med. 2023 Sep;29(9):2295-2306. doi: 10.1038/s41591-023-02491-5. Epub 2023 Aug 31.
7
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.先前接受过 BCMA 靶向治疗的多发性骨髓瘤患者使用 ide-cel 的真实世界经验。
Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8.
8
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。
N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.
9
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.伊达赛利珠单抗或标准方案治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.
10
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.双等位基因 BCMA 缺失导致多发性骨髓瘤患者对 CAR T 细胞治疗产生耐药。
Nat Commun. 2021 Feb 8;12(1):868. doi: 10.1038/s41467-021-21177-5.